MaxCyte, Inc. Finance Lease, Right-of-Use Asset, Amortization
MaxCyte, Inc. (MXCT) reported Finance Lease, Right-of-Use Asset, Amortization of $55.60 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2023-03-15
- MaxCyte, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- MaxCyte, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-09-30 was $7.90K, a 66.81% decline year-over-year.
- MaxCyte, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-06-30 was $23.80K, a 0.00% change year-over-year.
- MaxCyte, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-03-31 was $23.80K.
- MaxCyte, Inc. finance lease, right-of-use asset, amortization for fiscal 2021 was $55.60K, a 33.33% decline from fiscal 2020.
- MaxCyte, Inc. finance lease, right-of-use asset, amortization for fiscal 2020 was $83.40K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $7.90K derived: sum of 2 quarters · filed 2023-03-15 | $31.70K derived: sum of 3 quarters · filed 2023-03-15 | $55.60K 10-K · filed 2023-03-15 |
| 2021-09-30 | $7.90K 10-Q · filed 2022-11-09 | $31.70K derived: sum of 2 quarters · filed 2022-11-09 | $55.60K 10-Q · filed 2022-11-09 | $79.40K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $23.80K 10-Q · filed 2022-08-10 | $47.60K 10-Q · filed 2022-08-10 | $71.50K derived: sum of 3 quarters · filed 2022-08-10 | $95.30K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $23.80K 10-Q · filed 2022-05-09 | $47.70K derived: sum of 2 quarters · filed 2022-05-09 | $71.50K derived: sum of 3 quarters · filed 2022-05-09 | $95.30K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $23.90K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $47.70K derived: sum of 2 quarters · filed 2022-03-22 | $71.50K derived: sum of 3 quarters · filed 2022-03-22 | $83.40K 10-K · filed 2022-03-22 |
| 2020-09-30 | $23.80K 10-Q · filed 2021-11-10 | $47.60K derived: sum of 2 quarters · filed 2021-11-10 | $59.50K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $23.80K 10-Q · filed 2021-09-13 | $35.70K 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |